The efficacy of VEOZA was evaluated in two 12-week, randomised, placebo-controlled, double-blind Phase-3 studies, followed by a 40-week uncontrolled extension treatment period¹

Coprimary Endpoints¹:

Mean change from baseline in moderate to severe VMS frequency and severity

Participants in the study¹:

Self-identified as Caucasian (81%), African American (17%), Asian (1%), Hispanic/Latina ethnicity (24%). The mean age was 54 years. Included menopausal women with prior hormone therapy use (19.9%), with oophorectomy (21.6%), or with hysterectomy (32.1%)